Advertisement
UK markets close in 7 hours 35 minutes
  • FTSE 100

    7,885.66
    +37.67 (+0.48%)
     
  • FTSE 250

    19,393.70
    +53.56 (+0.28%)
     
  • AIM

    743.20
    +0.08 (+0.01%)
     
  • GBP/EUR

    1.1677
    +0.0010 (+0.08%)
     
  • GBP/USD

    1.2474
    +0.0018 (+0.14%)
     
  • Bitcoin GBP

    49,099.09
    -1,866.17 (-3.66%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • DOW

    37,753.31
    -45.66 (-0.12%)
     
  • CRUDE OIL

    82.19
    -0.50 (-0.60%)
     
  • GOLD FUTURES

    2,390.20
    +1.80 (+0.08%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,414.79
    +162.95 (+1.00%)
     
  • DAX

    17,814.96
    +44.94 (+0.25%)
     
  • CAC 40

    8,020.42
    +38.91 (+0.49%)
     

What’s in AstraZeneca’s Research Pipeline for Fiscal 2019

What’s in AstraZeneca’s Research Pipeline for Fiscal 2019

In the second half of fiscal 2018, major news is expected for indications in diabetes, anemia, COPD (chronic obstructive pulmonary disease), and lupus in AstraZeneca’s (AZN) pipeline. A data readout is expected from the DECLARE trial for Farxiga for type 2 diabetes, and a regulatory decision in the European Union is expected for the Bydureon autoinjector for type 2 diabetes.